PA
CYTK icon

Profund Advisors’s Cytokinetics CYTK Stock Holding History

Profund Advisors’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.35M Sell
35,713
-3,929
-10% -$250K 0.09% 164
2025
Q4 		$2.52M Buy
39,642
+13,712
+53% +$853K 0.08% 161
2025
Q3 		$1.43M Sell
25,930
-12,518
-33% -$516K 0.05% 255
2025
Q2 		$1.27M Buy
38,448
+4,413
+13% +$153K 0.05% 249
2025
Q1 		$1.37M Sell
34,035
-1,678
-5% -$77.1K 0.06% 238
2024
Q4 		$1.68M Sell
35,713
-10,339
-22% -$537K 0.06% 207
2024
Q3 		$2.43M Sell
46,052
-5,869
-11% -$327K 0.09% 164
2024
Q2 		$2.81M Buy
51,921
+25,400
+96% +$1.53M 0.1% 140
2024
Q1 		$1.86M Sell
26,521
-21,228
-44% -$1.64M 0.07% 184
2023
Q4 		$3.99M Buy
47,749
+1,870
+4% +$67.7K 0.17% 102
2023
Q3 		$1.35M Buy
45,879
+447
+1% +$14.9K 0.07% 219
2023
Q2 		$1.48M Buy
45,432
+5,358
+13% +$198K 0.08% 211
2023
Q1 		$1.41M Buy
40,074
+34,405
+607% +$1.4M 0.09% 199
2022
Q4 		$260K Sell
5,669
-574
-9% -$24.7K 0.02% 739
2022
Q3 		$302K Buy
6,243
+477
+8% +$23K 0.02% 589
2022
Q2 		$227K Sell
5,766
-1,089
-16% -$43.8K 0.01% 828
2022
Q1 		$252K Sell
6,855
-716
-9% -$25.4K 0.01% 1088
2021
Q4 		$345K Sell
7,571
-387
-5% -$14.9K 0.01% 878
2021
Q3 		$284K Buy
+7,958
New +$234K 0.01% 1001
2018
Q4 		– Sell
-10,029
Closed -$99K – 1219
2018
Q3 		$99K Sell
10,029
-966
-9% -$7.75K ﹤0.01% 1515
2018
Q2 		$91K Buy
+10,995
New +$91.5K ﹤0.01% 1469

Other funds holding CYTK

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Profund Advisors's CYTK Position: Q1 2026 in Review

Profund Advisors reduced its Cytokinetics (CYTK) stake by 9.9% in Q1 2026, selling an estimated $250K and leaving 35,713 shares worth $2.35M. The position accounts for 0.09% of the portfolio, ranked #164.

Profund Advisors first reported a position in CYTK in Q2 2018 and has held it in 21 quarters since. The position peaked at $3.99M in Q4 2023. 439 funds tracked by Wall St. Rank hold CYTK as of Q1 2026.

  • Profund Advisors held 35,713 shares of Cytokinetics worth $2.35M as of Q1 2026.
  • Profund Advisors sold 3,929 Cytokinetics shares in Q1 2026, an estimated $250K.
  • Cytokinetics made up 0.09% of Profund Advisors's portfolio in Q1 2026, its #164 holding.
  • Profund Advisors first reported a position in Cytokinetics in Q2 2018 and has held it in 21 quarters since.
  • Profund Advisors's Cytokinetics position peaked at $3.99M in Q4 2023.
  • 439 funds tracked by Wall St. Rank held Cytokinetics as of Q1 2026.

Based on Profund Advisors's 13F filing for Q1 2026, filed 27 Apr 2026.